Clinical Trial: NCT04523272
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Information Provided By: | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Last Update Posted: | 2024-10-15 |
Study Overview
Brief Summary
This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in subjects with advanced renal cancer.
Official Title
A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Conditions
Advanced Renal Cancer
Intervention / Treatment
- Drug: TQB2450
- Drug: Anlotinib
- Drug: Sunitinib
Other Study ID Numbers
- TQB2450-III-07
Start Date (Actual)
2020-08-25
Primary Completion Date (Estimated)
2025-06
Study Completion Date (Estimated)
2025-12
Enrollment (Actual)
528
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Information Provided By: | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Last Update Posted: | 2024-10-15 |
Study Overview
Brief Summary
This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in subjects with advanced renal cancer.
Official Title
A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Conditions
Advanced Renal Cancer
Intervention / Treatment
- Drug: TQB2450
- Drug: Anlotinib
- Drug: Sunitinib
Other Study ID Numbers
- TQB2450-III-07
Start Date (Actual)
2020-08-25
Primary Completion Date (Estimated)
2025-06
Study Completion Date (Estimated)
2025-12
Enrollment (Actual)
528
Study Type
Interventional
Phase
Phase 3